Latest news
5033 articles · 20 / page
Optimizing Postpartum Pain Management: Addressing Hospital Variation in Opioid Prescribing Following Vaginal Birth and Associated Procedures
This review analyzes significant inter-hospital variations in opioid prescribing for vaginal births with complications, highlighting the need for standardized postdischarge pain management protocols to reduce unnecessary opioid exposure.
Y90 Radioembolization as a Bridge to Liver Transplantation in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
Y90 radioembolization downstaged about one-quarter of HCC patients with portal vein tumor thrombosis to transplant eligibility, and those who received liver transplantation had markedly better cancer-related outcomes and survival.
Adipocyte-Driven Immunometabolic Suppression in Pancreatic Cancer: The 12,13-DiHOME/PPARγ/TAN Axis
This review explores how tumour-infiltrating adipocytes release 12,13-DiHOME to trigger neutrophil ferroptosis and CXCL2 production, ultimately subverting CD8+ T cell-mediated immunity in pancreatic ductal adenocarcinoma.
Quorum-Sensing Molecules Elevated in Long-Standing Ulcerative Colitis May Help Drive Colitis-Associated Cancer
Bacterial quorum-sensing molecules, especially C6-scAHL, were elevated in long-standing ulcerative colitis and promoted colon tumor growth in mice, suggesting a new microbiome-driven pathway for colitis-associated cancer.
Application of the AHA-Proposed Cancer-Related Ischemic Stroke Classification: Reclassification and Prognostic Impact
The AHA-proposed CRIS classification reclassified many cancer-associated strokes previously labeled cryptogenic and identified a subgroup with markedly worse survival, improving both etiologic clarity and prognostic stratification.
Midlife Central Obesity Tracks With Higher Late-Life Plasma P-tau217 and Biomarker-Verified Alzheimer Dementia, While the Association Reverses in Old Age
In the HUNT Study, higher midlife waist-to-height ratio and BMI predicted higher late-life plasma p-tau217 and biomarker-verified Alzheimer dementia, whereas higher adiposity in late life was associated with lower biomarker levels and lower
Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial
In a randomized trial of large-vessel-occlusion stroke, standard-dose tenecteplase improved early reperfusion before thrombectomy compared with low-dose alteplase, with similar safety and functional outcomes.
Standard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial
In patients with large-vessel-occlusion stroke undergoing thrombectomy, standard-dose tenecteplase achieved more early reperfusion than low-dose alteplase, with similar safety and functional outcomes.
New Genetic Modifiers in Autosomal Dominant Alzheimer’s Disease Link Aβ, Tau, TDP-43, and Vascular Biology to Clinical Variability
A genome-wide association study identified CNIH4, CCNG1, and RHOJ as genetic modifiers of autosomal dominant Alzheimer’s disease, with associations spanning disease risk, age at onset, fluid biomarkers, and neuroimaging phenotypes.
Detectable Antithyroglobulin Antibodies Above the Assay LOQ Signal Higher Recurrence Risk in Papillary Thyroid Carcinoma Despite Undetectable Thyroglobulin
In papillary thyroid carcinoma treated with thyroidectomy and RAI, TgAb levels above the assay’s limit of quantification identified patients with higher long-term recurrence risk despite undetectable serum thyroglobulin.
Beta Cell Glucose Sensitivity May Predict Response to New-Onset Type 1 Diabetes Therapies
A pooled analysis of nine type 1 diabetes trials found that beta cell glucose sensitivity may better predict response to disease-modifying therapy than C-peptide alone, helping identify patients most likely to benefit.
Genetic Evidence Strengthens High BMI as a Causal Driver of Vascular Dementia, With Blood Pressure as a Partial Mediator
A 2026 Mendelian randomization study supports high BMI as a causal risk factor for vascular-related dementia, with part of the effect mediated through elevated systolic and diastolic blood pressure.
Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure
A validated model, SABRE, estimates who with type 2 diabetes may gain the most heart-failure prevention benefit from SGLT2 inhibitors, enabling more precise, individualized prescribing.
Bempedoic Acid Was Linked to Fewer Venous Thromboembolic Events in Statin-Intolerant Patients in CLEAR Outcomes
In a post hoc analysis of CLEAR Outcomes, bempedoic acid was associated with a significantly lower risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, among statin-intolerant patients at high cardiovascula
Thyroid Dysfunction Is a Cardiovascular Risk Multiplier, but Treatment Benefits Depend on Phenotype, Severity, and Age
Thyroid dysfunction reshapes lipid metabolism, vascular tone, cardiac performance, and rhythm. Cardiovascular risk is clearest at the extremes of thyroid status, while treatment decisions in subclinical disease should remain individualized.
Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial
Continuous ICM monitoring in heart failure found a high burden of atrial fibrillation, bradyarrhythmia, and VT/VF. Arrhythmias were linked to more interventions and higher hospitalization risk, but the congestion-management strategy did not
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.
Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy Versus Right Unilateral Ultra-Brief Electroconvulsive Therapy in Depression
Magnetic seizure therapy was non-inferior to right unilateral ultra-brief ECT for depression remission and caused less autobiographical memory worsening, suggesting a promising convulsive treatment option with better cognitive safety.
Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial
A small randomized trial found that blocking IL-6 with tocilizumab showed promising, clinically meaningful trends for inflammation-related, hard-to-treat depression, especially for somatic symptoms, fatigue, anxiety, and quality of life, th
Browse by specialty
Open language-specific specialty feeds and department pages.